3a. Chronic lung disease at 36 weeks' postmenstrual age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
4a. Death (at any time during initial hospitalization) – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
4b. Death (at any time during initial hospitalization) – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · prevention of reintubation
It is very uncertain whether doxapram changes 4c. Death (at any time during initial hospitalization) – doxapram as… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
1 finding from 1 review
5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
6a. Side effects causing cessation of therapy – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
side‐effects ‐ side‐effects causing abandon · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
BPD (36 weeks' PMA) · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes BPD, defined as supplemental oxygen or positive pressure support use… compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes BPD, defined as supplemental oxygen or positive pressure support use… compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
1 finding from 1 review
Retinopathy of prematurity · preterm infants
Enteral zinc supplementation showed no clear difference in retinopathy of prematurity compared with no zinc supplementation (low certainty).
1 finding from 1 review
Use of conventional phototherapy, if sunlight (with or without filters or amplification) was first used for prevention or early treatmentc · term and late preterm neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Presence of PDA on third to fourth day of life (after 72 hours of treatment) · preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
The intervention probably leads to lower presence of PDA on third to fourth day of life (after 72 hours of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Presence of PDA on third day of life (72 hours of treatment) · preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
1 finding from 1 review
Intervention not reported
Presence of PDA on day 3 or 4 of life (after 72 hours of treatment) · preterm or low birth weight infants with risk of having PDA on day 3 to 4 of life
The intervention may leads to lower presence of PDA on day 3 or 4 of life (after 72 hours of treatment) (low certainty).
1 finding from 1 review
Intervention not reported
BSID‐III composite cognitive scores at 18 to 22 months The Bayley‐III has 3 main sub tests: the Cognitive Scale, which includes items such as attention to familiar and unfamiliar objects, looking for a fallen object, and pretend play; the Language... · neonates born preterm with low birth weight
The intervention probably leads to higher BSID‐III composite cognitive scores at 18 to 22 months The… (moderate certainty).
1 finding from 1 review
Intervention not reported
Retinopathy of prematurity (stage ≥ 3) · preterm infants with low birth weight
The intervention showed no clear difference in retinopathy of prematurity (stage ≥ 3) (high certainty).
1 finding from 1 review
Intervention not reported
Retinopathy of prematurity (all stages or stage not reported) during initial hospital stay · preterm infants with low birth weight
It is very uncertain whether the intervention changes retinopathy of prematurity (all stages or stage not reported) during… (very low certainty).
1 finding from 1 review